The use and safety of intramuscular midazolam during in-office botulinum toxin injections in pediatric patients.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
72 patients from a Tertiary Pediatric Hospital Outpatient Clinic.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Intramuscular midazolam is a possible effective anxiolytic medication strategy for outpatient pediatric injections. Additional studies are needed to ensure its safety and efficacy.
[PURPOSE] Pediatric outpatient procedures can be traumatic experiences for patients.
- 95% CI 26.51-31.35
APA
Mian MN, Alwasiah N, Savitz A (2021). The use and safety of intramuscular midazolam during in-office botulinum toxin injections in pediatric patients.. Journal of pediatric rehabilitation medicine, 14(2), 213-218. https://doi.org/10.3233/PRM-190629
MLA
Mian MN, et al.. "The use and safety of intramuscular midazolam during in-office botulinum toxin injections in pediatric patients.." Journal of pediatric rehabilitation medicine, vol. 14, no. 2, 2021, pp. 213-218.
PMID
33896852 ↗
Abstract 한글 요약
[PURPOSE] Pediatric outpatient procedures can be traumatic experiences for patients. This retrospective study, evaluates intramuscular midazolam as a safe option for anxiolysis during spasticity management injections.
[METHODS] We performed a retrospective chart review of 72 patients from a Tertiary Pediatric Hospital Outpatient Clinic. One hundred and twenty injections were administered over two years by a single practitioner. Comorbidities included asthma, sleep apnea, chronic obstructive disease, and epilepsy. Duration of sedation, safety of midazolam as determined through the use of the REACT (Respiration, Energy, Alertness, Circulation, Temperature) score, and frequency of side effects (prolonged sedation, breakthrough crying, medication reversal, and emergent evaluation) were recorded. A student's t test evaluated the relationship between the above comorbidities and duration of sedation.
[RESULTS] The average duration of sedation was 29 minutes (95% CI 26.51-31.35) with an average dose of midazolam of 0.20 mg/kg (95% CI 0.9-0.21). None of the subjects required medication reversal or emergent evaluation. 39% of the patients had prolonged sedation (> 30 minutes after medication administration), 22% had breakthrough crying, and 0% had respiratory events requiring oxygen, intubation or an emergency evaluation. No statistical significance found between the comorbidities and duration of sedation.
[CONCLUSION] Intramuscular midazolam is a possible effective anxiolytic medication strategy for outpatient pediatric injections. Additional studies are needed to ensure its safety and efficacy.
[METHODS] We performed a retrospective chart review of 72 patients from a Tertiary Pediatric Hospital Outpatient Clinic. One hundred and twenty injections were administered over two years by a single practitioner. Comorbidities included asthma, sleep apnea, chronic obstructive disease, and epilepsy. Duration of sedation, safety of midazolam as determined through the use of the REACT (Respiration, Energy, Alertness, Circulation, Temperature) score, and frequency of side effects (prolonged sedation, breakthrough crying, medication reversal, and emergent evaluation) were recorded. A student's t test evaluated the relationship between the above comorbidities and duration of sedation.
[RESULTS] The average duration of sedation was 29 minutes (95% CI 26.51-31.35) with an average dose of midazolam of 0.20 mg/kg (95% CI 0.9-0.21). None of the subjects required medication reversal or emergent evaluation. 39% of the patients had prolonged sedation (> 30 minutes after medication administration), 22% had breakthrough crying, and 0% had respiratory events requiring oxygen, intubation or an emergency evaluation. No statistical significance found between the comorbidities and duration of sedation.
[CONCLUSION] Intramuscular midazolam is a possible effective anxiolytic medication strategy for outpatient pediatric injections. Additional studies are needed to ensure its safety and efficacy.
추출된 의학 개체 (NER)
시술
보툴리눔독소 주사
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Whole-body MRI for staging and follow-up of primary musculoskeletal tumours: a systematic review.
- Impact of prior endoscopic or surgical interventions on clinical outcomes after peroral endoscopic myotomy for achalasia.
- Procedural State Anxiety in Pediatric Leukemia Patients Undergoing Bone Marrow Aspiration or Lumbar Puncture: A Cross-Sectional Study Using the Chinese Version of the State Anxiety Scale for Children.
- Pegasparaginase-induced hepatotoxicity in patients with acute lymphocytic leukemia in the Saudi population: A retrospective cohort study.
- Characterization of liver disease in a cohort of individuals with Niemann-Pick Disease, Type C1.
- Hyperleukocytosis and Access to Minimal Residual Disease Testing Impact Outcomes in Children With Newly Diagnosed Acute Myeloid Leukemia in Thailand.
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
- Mechanisms of Botulinum Toxin Type A Action on Pain.
- Effect of Botulinum Toxin Injection on EMG Activity and Bite Force in Masticatory Muscle Disorder: A Randomized Clinical Trial.
- Botulinum Toxin: An Update on Pharmacology and Newer Products in Development.
- Immunogenicity of botulinum toxin.
- Botulinum Toxin in the Treatment of Headache.